Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean L Chan

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal HyperplasiaKyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 19, 2018
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With PlaceboCatherine T Frenette, Giuseppe Morelli, Mitchell L Shiffman, et al.
Journal of Hepatology|December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosisStephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal HyperplasiaRichard J Auchus, Oksana Hamidi, Rosario Pivonello, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal HyperplasiaKyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 19, 2018
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With PlaceboCatherine T Frenette, Giuseppe Morelli, Mitchell L Shiffman, et al.
Journal of Hepatology|December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosisStephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal HyperplasiaRichard J Auchus, Oksana Hamidi, Rosario Pivonello, et al.
Pageof 5